Changes in doxorubicin distribution and toxicity in mice pretreated with the cyclosporin analogue SDZ PSC 833 (original) (raw)
References
Bartlett NL, Lum BL, Fisher GA, Brophy NA, Ehsan MN, Halsey J, Sikic BI (1994) Phase I trial of doxorubicin with cyclosporine as a modulator of multidrug resistance. J Clin Oncol 4:835 Google Scholar
Bates SE (1993) Clinical reversal of multidrug resistance. Proc Am Assoc Cancer Res 34:568 Google Scholar
Boesch D, Loor F (1994) Extent and persistence of P-glyco-protein inhibition in multidrug-resistant P388 cells after exposure to resistance-modifying agents. Anticancer Drugs 5: 229 Google Scholar
Boesch D, Gaveriaux C, Jachez B, Pourtier-Manzanedo A, Bollinger P, Loor F (1991) In vivo circumvention of P-glycoprotein-mediated multidrug resistance of tumor cells with SDZ PSC 833. Cancer Res 51:4226 Google Scholar
Boesch D, Muller K, Pourtier-Manzanedo A, Loor F (1991) Restoration of daunomycin retention in multidrug-resistant P388 cells by submicromolar concentrations of SDZ PSC 833, a nonimmunosuppressive cyclosporin derivative. Exp Cell Res 196: 26 Google Scholar
Boote DJ, Dennis IF, Twentyman PR, Osborne RJ, Laburte C, Hensel S, Bleehen NM (1994) A phase I study of intravenous SDZ PSC-833 in combination with etoposide in patients with advanced cancer. Ann Oncol 5 [Suppl 5]:159 Google Scholar
Broggini M, Italia C, Colombo T, Marmonti L, Donelli MG (1984) Activity and distribution of iv and oral 4-demethoxydaunorubicin in murine experimental tumors. Cancer Treat Rep 68:739 Google Scholar
Colombo T, Zucchetti M, D'lncalci M (1994) Cyclosporin A markedly changes the distribution of doxorubicin in mice and rats. J Pharmacol Exp Ther 269:22 Google Scholar
Croop JM, Raymond M, Haber D, Devault A, Arceci RJ, Gros P, Housman DE (1989) The tree mouse multidrug resistance (mdr) genes are expressed in a tissue-specific manner in normal mouse tissues. Mol Cell Biol 9:1346 Google Scholar
Duran GE, Gosland MP, Ho AL, Sikic BL (1994) In vitro modulation of multidrug resistance (MDR) using human patient serum from EP-1: a phase I clinical trial of etoposide (VP-16) and SDZ PSC 833. Proc Am Assoc Cancer Res 35:351 Google Scholar
Endicott JA, Ling V (1989) The biochemistry of P-glyco-protein-mediated multidurg resistance. Annu Rev Biochem 58: 137 Google Scholar
Fisher GA, Hausdorff J, Collins H, Brophy N, Duran GE, Ehsan M, Nix D, Halsey J, Sikic BI (1994) Phase I clinical trial of etoposide with PSC 833, a potent inhibitor of multidrug resistance (MDR). Ann Oncol 5 [Suppl 5]:158 Google Scholar
Fojo AT, Ueda K, Slamon DJ, Poplak DG, Gottesman MM, Pastan I (1987) Expression of a multidrug-resistance gene in human tumors and tissues Proc Natl Acad Sci USA 84: 265 Google Scholar
Ford JM, Hait WN (1990) Pharmacology of drugs that alter multidrug resistance in cancer. Pharmacol Rev 42:155 Google Scholar
Friche E, Jensen PB, Nissen NI (1992) Comparison of cyclosporin A and SDZ PSC833 as multidrug-resistance modulators in a daunorubicin-resistant Ehrlich ascites tumor. Cancer Chemother Pharmacol 30:235 Google Scholar
Gaveriaux C, Boesch D, Jachez B, Bollinger P, Payne P, Loor F (1991) SDZ-PSC-833, a non-immunosuppressive cyclo-sphorine analog, is a very potent multidrug-resistance modifier. J Cell Pharmacol 2:225 Google Scholar
Gottesman MM (1993) How cancer cells evade chemotherapy: 16th Richard and Hinda Rosenthal Foundation Award Lecture. Cancer Res 53:747 Google Scholar
Gottesman MM, Pastan I (1993) Biochemistry of multidrug resistance mediated by the multidrug transporter. Annu Rev Biochem 62:385 Google Scholar
Kaye SB (1993) P-glycoprotein (P-gp) and drug resistance-time for reappraisal? Br J Cancer 67:641 Google Scholar
Keller RP, Altermatt HJ, Nooter K, Poschmann G, Laissue JA, Bollinger P, Hiestand PC (1992) SDZ PSC 833, a non-immuno-suppressive cyclosporin: its potency in overcoming P-glycoprotein-mediated multidrug resistance of murine leukemia. Int J Cancer 50:593 Google Scholar
Lum BL, Kaubisch S, Yahanda AM, Adler KM, Jew L, Ehsan MN, Borphy NA, Halsey J, Gosland MP, Sikic BI (1992) Alteration of etoposide pharmacokinetics and pharmacodinamics by cyclosporine in a phase I trial to modulate multidrug resistance. J Clin Oncol 10:1635 Google Scholar
Lum BL, Fisher GA, Brophy NA, Yahanda AM, Alder KM, Kaubisch S, Halsey J, Sikic BL (1993) Clinical trials of modulation of multidrug resistance. Cancer 72:3502 Google Scholar
Pastan I, Gottesman M (1987) Multidrug resistance in human cancer. N Engl J Med 316:1388 Google Scholar
Rushing DA, Raber SR, Rodvold KA, Piscitelli SC, Plank GS, Tewksbury DA (1994) The effects of cyclosporine on the pharmacokinetics of doxorubicin in patients with small cell lung cancer. Cancer 74:834 Google Scholar
Sikic BI (1993) Modulation of multidrug resistance: at the threshold. J Clin Oncol 11:1629 Google Scholar
Slater LM, Sweet P, Stupecky M, Gupta S (1986) Cyclosporin A reverses vincristine and daunomicin resistance in acute lymphatic leukemia in vitro. J Clin Invest 77:1405 Google Scholar
Sonneveld P, Marie JP, Laburte C, Schoester M (1994) Phase I study of SDZ PSC833, a multidrug resistance modulating agent, in refractory multiple myeloma. Proc Am Assoc Cancer Res 35:359 Google Scholar
Sugawara I, Kataoka I, Morishita Y, Hamada H, Tsuruo T, Itoyama S, Mori S (1988) Tissue distribution of P-glycoprotein encoded by a multidrug-resistant gene as revelaed by a monoclonal antibody, MRK 16. Cancer Res 48:1926 Google Scholar
Twentyman PR (1992) Cyclosporins as drug resistance modifiers. Biochem Pharmacol 43:109 Google Scholar
Twentyman PR, Bleehen NM (1991) Resistance modification by PSC-833, a novel non-immunosuppressive cyclosporin A. Eur J Cancer 27:1639 Google Scholar
Van Der Bliek AM, Borst P (1989) Multidrug resistance. Adv Cancer Res 52:165 Google Scholar
Yahanda AM, Alder KM, Fisher GA, Brophy NA, Halsey J, Hardy RI, Gosland MP, Lum BL, Sikic BI (1992) Phase I trial of etoposide with cylosporine as a modulator of multidrug resistnace. J Clin Oncol 10:1624 Google Scholar